Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Sarcoma: early-phase trial registry
58 of 129 indexed Sarcoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #92 of 28,707 conditions by registered trial count.
129 US clinical trials · 58 currently recruiting · #92 of 28,707 conditions by registered trial count
Sarcoma: 129 US clinical trials tracked, 58 recruiting.
Sarcoma is the subject of 129 registered US clinical trials on ClinicalTrials.gov, 58 of them currently open to new participants. 10 are in Phase 3-4 (later-stage) and 80 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 26 of these trials.
Enrollment posture brief
Registry condition sarcoma
OPEN 58 | RECR 45% | LATE 10 | EARLY 80 | RANK #92 | SPON 26
Volume-matched condition peers
Nearest open-share peer: Cancer (45% recruiting · 621 trials)
Sarcoma lists 58 open slots (45% of 129 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Sarcoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Sarcoma is recruiting above its size-band peers.
58 of 129 indexed trials (45%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Sarcoma research.
Memorial Sloan Kettering Cancer Center accounts for 26 of 129 trials (20.2%). 72 distinct sponsors appear on at least one study for this condition label.
-
Most Sarcoma trials plan to enrol fewer than 100 people.
Median target enrolment is 60 among the 123 trials that report a genuine target (sentinel values excluded). 80 of those (65%) plan for fewer than 100 participants.
-
Sarcoma research is mostly interventional.
106 interventional and 23 observational studies make up this index (82.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
129 total, page 1 of 3
Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program
M.D. Anderson Cancer Center
NCT01772771
Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies
National Cancer Institute (NCI)
NCT01109394
Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
Northwestern University
NCT00005095
Pediatric Radiation Therapy Registry
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT07129317
Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma
Memorial Sloan Kettering Cancer Center
NCT00579566
Cohort to Augment the Understanding of Sarcoma Survivorship Across the Lifespan
Vanderbilt-Ingram Cancer Center
NCT06482957
Video Education With Result Dependent dIsclosure
Dana-Farber Cancer Institute
NCT05225428
PROMIS and Mobility Evaluation in Sarcoma Patients
University of Calgary
NCT07227961
BostonGene and Exigent Genomic INsight Study
BostonGene
NCT06272864
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
National Cancer Institute (NCI)
NCT06503146
LCI-SAR-BSTS-CTDNA-001: Circulating Tumor DNA Liquid Biopsy in Sarcoma Patients
Wake Forest University Health Sciences
NCT06958107
GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma
Sarcoma Oncology Research Center
NCT04535713
Symptom Management and Transitioning to Engagement With Post-treatment Care for Adolescent and Young Adult Cancer Survivors
Duke University
NCT06371768
WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring)
Mayo Clinic
NCT07058064
A Study of MGC026 in Participants With Advanced Solid Tumors
MacroGenics
NCT06242470
Locally AblatiVe TherApy in OLigO-pRogressive SOlid TUmorS (VALOROUS)
University of California, Davis
NCT06103669
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
Udai Kammula
NCT03935893
Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma
Sarcoma Oncology Research Center
NCT03886311
Disease Outcomes and Toxicities in Patients With Gastrointestinal and Sarcomatous Malignancies
UNC Lineberger Comprehensive Cancer Center
NCT05743426
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
Epkin
NCT06789172
First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
Daiichi Sankyo
NCT06644755
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
EpicentRx
NCT04673942
Enhanced Recovery After Surgery in Extremity Sarcoma
Joshua Lawrenz
NCT04461171
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Perspective Therapeutics
NCT06710756
Fluorescent Intra-operative Tumor Margin Examination
Kurt Weiss
NCT04719156
Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
Washington University School of Medicine
NCT04354064
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
Memorial Sloan Kettering Cancer Center
NCT04577014
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
Nationwide Children's Hospital
NCT05135975
IDOV-Immune for Advanced Solid Tumors
ViroMissile
NCT06910657
A Study of CRD3874-SI in People With Solid Tumors
Memorial Sloan Kettering Cancer Center
NCT06021626
SLV-154 Treatment of Metastatic Solid Tumors
Solve Therapeutics
NCT06771219
Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
David S Shulman, MD
NCT06709495
Study Assessing the Effects of Early Psychiatric Referral on Mental Health and Quality of Life in People With Sarcoma
Memorial Sloan Kettering Cancer Center
NCT06129903
GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2
Y-mAbs Therapeutics
NCT05130255
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
National Cancer Institute (NCI)
NCT02390752
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
University of California, Irvine
NCT06580002
Abductor Reattachment Methods in Proximal Femur Replacements: What is the Best Method?
Duke University
NCT03261544
Recognition of Circulating Tumor DNA in Soft Tissue Sarcoma
Medical College of Wisconsin
NCT03896620
Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas
St. Jude Children's Research Hospital
NCT07222735
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
Crystal Mackall, MD
NCT06500819
Effect of A Multimodal Exercise Intervention on Chemotherapy Uptake in Newly Diagnosed Pediatric and AYA Sarcoma Patients
University of Miami
NCT07359911
Biomarkers of Resiliency In Childhood Cancer Surgery
Mayo Clinic
NCT06674811
Brief Title Mechanisms of Cancer-Related Pain and Opioid Use Among Adolescents and Young Adult Sarcoma Survivors: Pilot Feasibility Study
Roswell Park Cancer Institute
NCT07402577
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT03465592
A Study of Pembrolizumab in People With Ultra-Rare Sarcomas
Memorial Sloan Kettering Cancer Center
NCT07089992
Phase II Trial of Lung Chemoemobolization
City of Hope Medical Center
NCT05672108
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
ImmVira Pharma Co.
NCT04370587
A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg
Memorial Sloan Kettering Cancer Center
NCT04332874
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
Lantheus Medical Imaging
NCT06298916
HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
Baylor College of Medicine
NCT04995003
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 37 |
| Phase 2 | 43 |
| Phase 3 | 8 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Sarcoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Sarcoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Sarcoma page
129 registered trials, 58 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 58 Sarcoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Sarcoma trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Sarcoma condition card totals 129 registered trials; most-linked intervention filgrastim; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.